US Pat. No. 9,168,291

?-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY

The United States of Amer...

1. A method for activating a mammalian NKT cell in vitro comprising:
culturing in vitro a mononuclear cell fraction comprising one or more mammalian NKT cells in the presence of a composition
in an amount sufficient to activate a mammalian NKT cell in vitro,

wherein the composition comprises a ?-mannosylceramide (?-ManCer) or salt or solvate thereof in a pharmaceutically acceptable
carrier, wherein the ?-ManCer consists of a ?-mannosyl moiety linked to a ceramide moiety, the ceramide moiety consisting
of:

a) a sphingosine moiety linked to
b) a fatty acid moiety comprising a linear or branched, saturated or unsaturated, aliphatic hydrocarbon group having from
about 8 to about 49 carbon atoms.

US Pat. No. 9,421,220

ANTI-CANCER COMPOSITION COMPRISING ALGINATE

THE UNIVERSITY OF BIRMING...

1. A method of treating a mammal afflicted with colorectal cancer, the method comprising the oral administration to a mammal
in need of a therapeutically effective amount of a biologically acceptable composition comprising an iron chelator, wherein
the composition is encapsulated or microencapsulated by a coating which remains intact while the composition passes through
the stomach and small intestine, but which degrades in the colon, such that the iron chelator is prevented from binding iron
until it reaches the colon, and wherein the iron chelator is non-digestible, non-absorbable and non-fermentable in the gastrointestinal
tract.
US Pat. No. 9,517,243

BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY

The United States of Amer...

1. A composition comprising a ?-mannosylceramide (?-ManCer) or salt or solvate thereof in a pharmaceutically acceptable carrier,
wherein the ?-ManCer consists of a ?-mannosyl moiety linked to a ceramide moiety, the ceramide moiety consisting of:
a) a sphingosine moiety linked to
b) a fatty acid moiety comprising a linear or branched, saturated or unsaturated, aliphatic hydrocarbon group having from
about 8 to about 49 carbon atoms, wherein the composition further comprises a therapeutically effective amount of one or more
chemotherapeutic agents.

US Pat. No. 9,594,265

OPTICAL ABSORBER

The University of Birming...

1. An optical absorber comprising:
a semiconductor micro or nano scale structured array configured for transmission of infrared electromagnetic (EM) radiation
when in a passive state and for absorption and/or reflection of electromagnetic (EM) radiation when in an active state; and

an activator arranged to inject free carriers into the structured array to achieve plasmonic resonance conditions, thereby
to activate said array on demand.

US Pat. No. 9,561,266

TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS

University of Virginia Pa...

1. A composition comprising:
(a) at least one synthetic target peptide, wherein each synthetic target peptide:
(i) is between 8 and 50 amino acids long, and
(ii) comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2164-2167 and 2374; and
(b) a therapeutically effective amount of an adjuvant.

US Pat. No. 9,879,985

SIMULTANEOUS MULTIPLE VIEW SURFACE GEOMETRY ACQUISITION USING STRUCTURED LIGHT AND MIRRORS

The University of Birming...

1. A method of generating surface geometry information of an object within an imaged region using an imaging system comprising
a camera and a source of structured light comprising a source of a plurality of rays of light, the method comprising:
obtaining first image data comprising a plurality of pixels, the first image data comprising phase wrapped image data representing
the object and first structured light incident on the object, the first structured light comprising a periodic pattern comprising
a plurality of sinusoidal pattern elements and having a first spatial frequency projected from said source of structured light;

obtaining second image data comprising a plurality of pixels, the second image data comprising image data representing the
object and providing information associating each of the plurality of image pixels of the second image data with a ray of
said source of structured light;

processing the first image data based upon the second image data to determine a relationship between each of the plurality
of image pixels of the first image data and a pattern element of said pattern of the first structured light projected from
said source of structured light, wherein said processing comprises unwrapping the phase of the first image data based upon
the second image data; and

generating the surface geometry information of said object based upon the determined relationship and position data indicating
relative spatial positions of said camera and said source of structured light,

wherein the second image data is generated based upon third image data comprising image data representing the object and second
structured light incident on the object, wherein the second structured light comprises at least one of:

a periodic pattern comprising a second plurality of sinusoidal pattern elements having a second spatial frequency projected
from said source of structured light, wherein the first spatial frequency is greater than the second spatial frequency, and

at least one binary pattern, wherein the second image data comprises a binary encoding associating each of the plurality of
image pixels of the second image data with a ray of said source of structured light.

US Pat. No. 9,683,004

COATED NANOPARTICLES

The University of Birming...

1. A composition comprising nanoparticles of a noble metal, wherein the noble metal is functionalised with at least one type
of metal complex and surfactant, and wherein each nanoparticle has a loading of at least 500 and the surfactant is a fluorinated
polyether wherein the metal complex is a complex of a d-block, p-block or rare earth metal, and wherein the metal complex
is luminescent, radioactive or MRI active, or has anti-cancer activity.

US Pat. No. 9,943,598

NANOPARTICLES WITH ATTACHED DNA REPAIR INHIBITORS AND NUCLEAR LOCALISATION SIGNAL ELEMENTS

THE UNIVERSITY OF BIRMING...

1. A radio- or chemo-sensitizing compound comprising(i) a nanoparticle;
(ii) a DNA repair inhibitor; and
(iii) a nuclear localization signal element (NLS);
wherein the DNA repair inhibitor is attached to the nanoparticle, directly or via a linker moiety, and the NLS is attached to the DNA repair inhibitor or the linker moiety.

US Pat. No. 9,775,367

LOW FAT CHOCOLATE

The University of Birming...

1. A comestible product comprising a water-in-oil emulsion, the water-in-oil emulsion comprising cocoa butter type V fat-crystal
stabilized particles encapsulating an aqueous phase, the type V fat-crystal stabilized particles being dispersed substantially
through the cocoa butter continuous phase and one or more additional ingredients of chocolate, wherein the comestible product
is made by a method in which cocoa butter is heated, optionally with an emulsifier, and mixed to form a heated mixture, and
wherein the heated mixture is cooled to a temperature in the range of about 20° C. to about 30° C. to allow the type V fat-crystal
stabilized particles to form.

US Pat. No. 9,957,566

SCREENING METHOD

THE UNIVERSITY OF BIRMING...

1. A method of determining a probability value that is a diagnostic criterion associated with Alzheimer's disease in a human subject, the diagnostic criterion being derived from a cell cycle regulatory defect at G1/S phase transition and the presence of an apoE4 genotype; wherein the method comprises the steps of:i) obtaining a sample from the human subject;
ii) detecting the presence of a cell cycle regulatory defect at the G1/S phase transition in at least one non-neuronal cell from the sample obtained from the human subject in step i), wherein said detecting for the presence of a cell cycle regulatory defect at the G1/S phase transition is carried out by:
inducing cell division in the non-neuronal cell or cells from the sample from the human subject and testing the responsiveness of the cell or cells to a cell division inhibitor substance, wherein a reduced responsiveness to the cell division inhibitor substance in the cell or cells from the sample of the human subject, as compared to control cells not having a cell cycle regulatory defect at the G1/S phase transition, is an indication of the presence of a cell cycle regulatory defect at the G1/S phase transition; and
iii) detecting the presence of the apoE4 genotype from cells of the sample of the same human subject of step i),
wherein the result of step iii) and the result of step ii) are entered as variables into a diagnostic predictor equation in order to derive a probability value that is a diagnostic criterion associated with Alzheimer's disease;
wherein the diagnostic predictor equation has coefficients obtained by performing steps (i)-(iii) on a population of test human subjects and combining the results obtained by performing steps (i)-(iii) on a population of test human subjects by logistic regression.
US Pat. No. 9,402,916

RE-DIRECTED IMMUNOTHERAPY

THE UNIVERSITY OF BIRMING...

1. A method of retargeting T cells to cancer cells, the method comprising administering an agent for treating cancer to a
human subject in need thereof, wherein the agent comprises:
i) a targeting moiety that is capable of targeting to the cancer cells, wherein the targeting moiety is an antibody or antigen
binding fragment thereof that binds a tumor antigen; and

ii) a viral T cell epitope that elicits an existing immune response in the subject and binds to a HLA molecule on the surface
of the cancer cell of the human subject and has a HLA matched to the subject, and

iii) a peptide linker comprising a peptide cleavage site cleavable by a tumor associated protease and
wherein the linker can be selectively cleaved by the tumor associated protease to release the T cell epitope in the vicinity
of, and outside of, the cancer cell.

US Pat. No. 9,597,368

PEPTIDE AND USES THEREFOR

The University of Birming...

1. A method for treatment of a T-cell mediated autoimmune disease, comprising administering to a patient in need thereof:
a peptide consisting of no more than 20 amino acids and comprising N?-SVTEQGAELSNEER-C? (SEQ ID NO: 1) or an analogue or variant
thereof that inhibits T cell migration; or

a chimeric or fusion protein comprising said peptide,
wherein the disease is selected from the group consisting of diabetes mellitus (type 1), rheumatoid arthritis, Crohn's disease
and uveitis.

US Pat. No. 9,944,986

THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE

The University of Birming...

1. A method for detection of a combination of human single nucleotide polymorphisms (SNPs) in a human subject, comprisinga) obtaining a nucleic acid sample from said human subject;
b) genotyping the sample for a combination of SNPSs in rapamycin-sensitive gene(s) FAM5C, CRP, SYK, and ADRA1A, said combination of SNP alleles being rs725106 (A), rs1148613 (C), rs1341665 (A), rs290258 (G) and rs2036108 (T); and
c) detecting in said nucleic acid sample from said human subject the presence of an A for rs725106, a C for rs1148613, an A for rs1341665, a G for rs290258 and a T for rs2036108.
US Pat. No. 9,839,671

PEPTIDE AND USES THEREFOR

The University of Birming...

1. A method for treatment of Sjogren's syndrome by administration, to a patient, of:
a peptide consisting of no more than 20 amino acids and comprising N?-SVTEQGAELSNEER-C? (SEQ ID NO: 1) or an analogue or variant
thereof that inhibits T cell migration; or

a chimeric or fusion protein comprising said peptide.
US Pat. No. 9,650,445

IMMUNOTHERAPEUTIC MOLECULES AND USES

The University of Birming...

1. A composition for redirecting T cells to unwanted cells comprising:
(i) a targeting moiety capable targeting to unwanted cells wherein the targeting moiety is an anti-HER2 antibody or antigen
binding fragment thereof and wherein the targeting moiety is not masked, and

(ii) at least one further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety
to an immune cell, wherein the immune cell binding region is an anti-CD3 antibody or antigen binding fragment thereof, and
wherein the masked immune cell binding region is capable of being selectively unmasked by cleavage of at least one protease
cleavage site when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an
immune cell and,
wherein the further moiety is a scFv antibody in which the linker that joins the heavy chain variable domain (VH) and light
chain variable domain (VL) is of insufficient length, optionally a peptide linker of 14 or less amino acids, to allow pairing
of the VH and VL domains such that the scFv antibody cannot bind to the immune cell, and wherein, when in the vicinity of
the unwanted cells, pairing of the VH and VL domains occurs by selectively cleaving one or more cleavage sites in said linker
such that the VH and VL domains from the scFv antibody can bind to the immune cell.
US Pat. No. 9,358,282

RE-DIRECTED IMMUNOTHERAPY

The University of Birming...

1. An agent for retargeting T cells to cancer cells, the agent comprising:
(i) a targeting moiety that is capable of targeting to the cancer cells, wherein the targeting moiety is Rituximab or Cetuximab;
(ii) a T cell epitope capable of eliciting a T cell response in a subject, wherein the T cell epitope is NLVPMVATV (SEQ ID
NO: 21), and

(iii) a peptide linker comprising a peptide cleavage site cleavable by a tumor associated protease and
wherein the linker can be selectively cleaved by the tumor associated protease to release the T cell epitope in the vicinity
of, and outside of, the cancer cell.

US Pat. No. 9,663,843

MAGNET RECYCLING

The University of Birming...

1. A method for recovering rare earth particulate material from an assembly comprising a rare earth magnet having a coating,
the method comprising the steps of:
exposing the assembly to hydrogen gas to effect hydrogen decrepitation of the rare earth magnet whereby a rare earth particulate
material and coating particles are produced,

separating the rare earth particulate material and the coating particles from the rest of the assembly,
reducing the particle size of the rare earth particulate material to produce a rare earth powder without substantially changing
the particle size of the coating particles, and

separating the rare earth powder from the coating particles by passing the rare earth powder through at least one screen.

US Pat. No. 9,780,556

VOLTAGE SOURCED CONVERTER WITH SEMICONDUCTOR MODULES HANDLING A DC CURRENT FAULT

THE UNIVERSITY OF BIRMING...

1. A Voltage Sourced Converter (VSC) for a High Voltage Direct Current (HVDC) power converter, the VSC being a Multi-level
Modular Converter (MMC), the VSC comprising:
a bridge circuit for each of one or more phases of an AC network, the bridge circuithaving two arms, each arm connecting the supply to a pole of a DC terminal, wherein each arm of the bridge circuit has an
inductance, a branch equivalent impedance, one or more semiconductor modules capable of being switched between an on-condition,
in which a capacitor of the semiconductor module is in-line in the arm of the bridge circuit, and an off-condition, in which
the capacitor is out of line;
a DC current fault detection arrangement for detecting a fault arising within the VSC or at one or the other of the poles
of the DC terminal;

a built-in fault detector for detecting either AC faults or DC faults: and
a controller responsive to the detection of any of the current faults by the DC current detection arrangement and/or the built-in
fault detector for switching the one or more semiconductor modules in one of the arms of the bridge circuit to the on-condition,
and the one or more semiconductor modules of the other arm of the bridge circuit to the off-condition, such that electrical
energy stored in the capacitors and inductances is released in the form of an LC oscillation and the branch equivalent impedance
can be maximized in order to minimize AC current through the VSC.

US Pat. No. 9,523,086

PROTEIN EXTRACTION

The University of Birming...

1. A method for releasing the content of the periplasmic space of bacterial cells comprising incubating the bacterial cells
in a solution containing styrene maleic acid copolymer (SMA) so as to specifically disrupt the outer membrane of the bacterial
cells in order to release the content of the periplasmic space without disrupting the inner membrane, such that the content
of the periplasmic space is released, wherein the method comprises a further step of separating spheroplasts from the solution.
US Pat. No. 9,822,180

IMMUNOTHERAPEUTIC MOLECULES AND USES

THE UNIVERSITY OF BIRMING...

1. A composition for redirecting T cells to tumour cells comprising:
(i) a targeting moiety capable of targeting to tumour cells wherein the targeting moiety is an antibody or an antigen-binding
fragment thereof that specifically binds to an antigen expressed by the tumour cells and wherein the targeting moiety is not
masked, and

(ii) at least one further moiety that has a masked CD3- or T cell receptor (TCR)-binding region so as to prevent binding of
the further moiety to a T cell,

wherein the masked CD3- or TCR-binding region is capable of being selectively unmasked by cleavage of at least one protease
cleavage site when the molecule is in the vicinity of the tumour cells so as to allow binding of the further moiety to a T
cell and wherein the further moiety is a scFv antibody in which the linker that joins the heavy chain variable domain (VH)
and light chain variable domain (VL) is of insufficient length, optionally a peptide linker of 14 or less amino acids, to
allow pairing of the VH and VL domains such that the scFv antibody cannot bind to the T cell, and wherein, when in the vicinity
of the tumour cells, pairing of the VH and VL domains occurs by selectively cleaving one or more cleavage sites in said linker
such that the VH and VL domains from the scFv antibody can bind to the T cell.

US Pat. No. 10,106,621

IMMUNOTHERAPEUTIC MOLECULES AND USES

The University of Birming...

1. A method of preventing or treating a tumour, the method comprising (i) administering to a subject a molecule for redirecting T cells to tumour cellsor (ii) administering to a subject a molecule for redirecting T cells to tumour cells and a further therapeutic agent, which may include one or more of an immunostimulatory drug, an anti-cancer agent, and an inhibitor of an antibody response against the molecule of the invention,
wherein the molecule for redirecting T cells to tumor cells comprises:
(a) a targeting moiety capable of targeting to tumour cells wherein the targeting moiety is an antibody or an antigen-binding fragment thereof that specifically binds to an antigen expressed by the tumour cells and wherein the targeting moiety is not masked, and
(b) at least one further moiety comprising components of a T-cell binding region joined by at least one linker to the targeting moiety, wherein the T-cell binding region is masked so as to prevent binding of the further moiety to a T cell,
wherein the masked T-cell binding region is capable of being selectively unmasked by cleavage of at least one protease cleavage site when the molecule is in the vicinity of the tumour cells so as to allow binding of the further moiety to a T cell and wherein the
further moiety comprises separately a first VH and a first VL domain which when paired are capable of specifically binding to a T cell,
a linker comprising at least one protease cleavage site which joins the first VH domain to a second VL domain of a first masking moiety, and
a linker comprising at least one protease cleavage site which joins the first VL domain to a second VH domain of a second masking moiety,
and wherein the linker which joins the first VH domain to the second VL domain is of a sufficient length to allow pairing of the first VH domain to the second VL domain, and wherein the linker which joins the first VL domain to the second VH domain is of a sufficient length to allow pairing of the first VL domain to the second VH domain,
such that the first VH and first VL domains of the further moiety are not paired and the further moiety cannot bind to the T cell, and
wherein selective cleavage of the protease cleavage sites, when in the vicinity of the tumour cells, allows pairing of the first VH and first VL domains such that the further moiety can bind to the T cell.
US Pat. No. 9,795,671

USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS

BIOTIE THERAPIES CORP., ...

1. A method of alleviating a symptom of a fibrotic condition in a human subject in need thereof, said method comprising administering
to said human subject an effective amount of an anti-vascular adhesion protein-1 (VAP-1) antibody wherein said antibody is
a fully human recombinant antibody comprising a heavy chain polypeptide depicted in SEQ ID NO: 47 and a light chain polypeptide
depicted in SEQ ID NO: 48, wherein said symptom and fibrotic condition are selected from a group consisting of extracellular
matrix accumulation associated with skin fibrosis, fibrotic lung area associated with lung fibrosis, accumulation of collagen
around glomeruli or mesangial matrix expansion associated with renal nephropathy and pulmonary inflammation associated with
COPD.

US Pat. No. 10,099,369

GRASP MODELLING

The University of Birming...

1. A method of generating a configuration of a robotic hand for automatically grasping a first object, the robotic hand comprising a plurality of parts, the method comprising:receiving data representing the first object;
receiving a plurality of first models generated based upon an example grasp of a second object, the example grasp being based upon a configuration of the robotic hand for grasping the second object in which a plurality of parts of said hand contact said second object, each of said plurality of first models representing a relationship between a respective part of the robotic hand and a property of the second object associated with said part of the robotic hand, wherein the relationship is independent of any other part of the robotic hand;
receiving a second model generated based upon the example grasp, the second model representing a relationship between the plurality of parts of the robotic hand; and processing the data representing the first object based upon the plurality of first models to determine said configuration of the robotic hand for automatically grasping the first object.

US Pat. No. 10,138,261

FERROCENYL COMPOUNDS

THE UNIVERSITY OF BIRMING...

1. A pharmaceutical composition comprising a ferrocenyl compound having the general formula (I);
Wherein:
Het is a substituted or unsubstituted heterocyclic moiety;
L1, L2 and L3 are each a linker independently selected from alkylene, alkyleneoxy, alkyleneoxyalkylene, alkylenecarbonyl, alkyleneoxycarbonyl, alkyleneamido, alkyleneoxyamido, alkenylene, alkenyleneoxy, alkenylenecarbonyl, alkenyleneamido, alkynylene, alkynyleneoxy, alkynylenecarbonyl and alkynyleneamido, all of which may be straight chain or branched, substituted or unsubstituted;
R1 and R2 are each independently selected from H, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted arylcarbonyl, substituted or unsubstituted phosphate, substituted or unsubstituted phosphonate and substituted or unsubstituted phosphoramidate;
m and n are each 0 or 1; and
m+n?0.

US Pat. No. 10,342,113

CONTROLLED LASER IRRADIATION ATOM SOURCE

THE UNIVERSITY OF BIRMING...

1. A method of generating a vapour of neutral atoms of a specific species, the method comprising the steps of:positioning a sample material comprising a compound of the specific species, in a vacuum; and
irradiating the compound with a first laser, thereby to generate a vapour of neutral atoms of the specific species from the compound of the specific species, wherein the neutral atoms of the specific species in the vapour of neutral atoms of the specific species have a velocity of less than 50 ms?1, and wherein a power output of the first laser is selected such that an intensity at the sample material is less than 4 kW/cm2.
US Pat. No. 10,329,599

MOLECULAR DETECTION SYSTEM

The University of Birming...

1. A method of detecting a target nucleic acid molecule in a sample, said method comprising;providing an alignable scaffold/receptor complex, the receptor of said complex comprising a nucleic acid sequence which is complementary to at least a portion of the target nucleic acid molecule,
exposing the scaffold/receptor complex to the sample whereby to bind the receptor to the target nucleic acid molecule if present,
inducing alignment of the scaffold/receptor/target complex, and
using linear dichroism (LD) to detect a change in the alignment of the scaffold/receptor complex effected by binding of the target nucleic acid molecule, if present, to the receptor,
wherein at least a first and a second alignable scaffold/receptor complex are provided and
wherein each of the first and second scaffold/receptor complex binds to the same target nucleic acid, the receptor of the first complex comprising a nucleic acid sequence which is complementary to a first portion of the target nucleic acid, and the receptor of the second complex comprising a nucleic acid sequence which is complementary to a second portion of the target nucleic acid.

US Pat. No. 10,233,545

METHOD FOR PRODUCING PARTICULATE CLUSTERS

The University of Birming...

1. A method for producing particulate clusters, the method comprising passing a core through an array of coating particles supported by a matrix, such that collisions between the core and the coating particles cause the coating particles to become agglomerated and produce particulate clusters, wherein the matrix is formed from a condensed gas.
US Pat. No. 10,287,321

RE-DIRECTED IMMUNOTHERAPY

The University of Birming...

1. An agent for retargeting T cells to solid tumor cells, the agent comprising:(i) a targeting moiety that is capable of targeting to the solid tumor cells, wherein the targeting moiety is an antibody or antigen binding fragment thereof that binds a solid tumor antigen; and
(ii) a viral T cell epitope that elicits an existing immune response in the subject and binds to a HLA molecule on the surface of the cancer cell of the human subject and has a HLA matched to the subject,
(iii) a peptide linker comprising a peptide cleavage site cleavable by a tumor associated protease and
wherein the linker can be selectively cleaved by the tumor associated protease to release the T cell epitope in the vicinity of, and outside of, the solid tumor cells and wherein the solid tumor is not a lymphoma.

US Pat. No. 10,305,370

ELIMINATION OF COMMUTATION FAILURE BY HYBRID HVDC SYSTEM

The University of Birming...

1. A line commutated converter, LCC, for a high-voltage, direct current, HVDC, power converter, the LCC comprising at least one bridge circuit for connection to at least one terminal of a DC system, each bridge circuit comprising a plurality of arms, each associated with a respective phase of an AC system, each arm comprising:an upper and lower thyristor connected in series;
an associated branch extending from between the upper and lower thyristors; and
at least one capacitor module for each phase, the or each capacitor module operable to insert a capacitor into the respective arm of the bridge circuit in either polarity.